We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

LabMedica

Download Mobile App
Recent News Expo Clinical Chem. Molecular Diagnostics Hematology Immunology Microbiology Pathology Technology Industry Focus

Vircell Showcases Powerful Automation System and Ready-To-Use Diagnostic Kits at MEDICA 2022

By LabMedica International staff writers
Posted on 13 Nov 2022
Image: VIRCLIA LOTUS is based on VIRCLIA monotest technology to process infectious diseases inmunoassays (Photo courtesy of Vircell)
Image: VIRCLIA LOTUS is based on VIRCLIA monotest technology to process infectious diseases inmunoassays (Photo courtesy of Vircell)

Vircell (Granada, Spain) is participating in this year's edition of MEDICA, the world's largest annual medical technology trade fair, which is taking place from 14-17 November in Düsseldorf, Germany. More than 5,000 exhibitors from 70 countries are presenting their newest products and ideas at MEDICA which draws 120,000 trade visitors from over 170 countries every year.

At MEDICA 2022, Vircell is showcasing its all-in-one CLIA system, VIRCLIA LOTUS which is designed for the automatization of infectious serology with the VirCia Monotest kits. Vircell’s AmpliRun Total Controls are external run controls to monitor the accuracy and precision of the complete analytical process (extraction & amplification). These noninfectious lyophilized run controls include the complete inactivated microorganism in a matrix that mimics human specimens. In combination with the VirClia Monotests, laboratories can daily process a large panel of more than 80 tests with complete traceability. Thanks to the versatility of the VIRCLIA LOTUS fully-automated chemiluminescence solution and wide range of tests for infectious serology, laboratories can process their analysis on a daily basis, without the need to batch samples or refer them to outside centers.

Vircell is also highlighting its VIRPLEX Real Time PCR kits for infectious diseases testing alongside the Aspergillus Galactomannan Ag VIRCLIA Monotest. The test uses sandwich chemiluminescent immunoassay (CLIA) technology for the detection of Aspergillus galactomannan antigen in serum, plasma and human bronchoalveolar lavage (BAL) samples.

Related Links:
Vircell

Platinum Member
Automated Coagulation Analyzer
Hemolumi H6
New
Gold Member
Platelet Function Analyzer
PL-12
New
MR-proADM Test
B•R•A•H•M•S MR-proADM KRYPTOR test
Prefilled Tubes
Prefilled 5.0ml Tubes

Channels

Molecular Diagnostics

view channel
Image: The researchers Manel Pérez Pons y Carlos Rodriguez Muñoz at the IRBLleida laboratory (Photo courtesy of IRBLleida)

New Blood RNA Markers Help Advance Precision Medicine for Respiratory Patients

Risk stratification in hospitalized respiratory disease, particularly among older adults with COVID-19, remains challenging despite rich clinical datasets. Blood-based non-coding RNA biomarkers are promising,... Read more

Microbiology

view channel
Image: The “broth” used to monitor red blood cell depletion in whole blood spiked with one colony-forming-unit of E. coli bacteria, each incubated at different orbital shaking speeds—left to right: 0 RPM, 65 RPM, 120 RPM and 200 RPM—after four hours of incubation. This culturing raises a bacteria-rich, plasma-like layer of bacteria to the top of the vials, while clusters of stuck blood cells known as a Rouleaux formation sink to the bottom. (Image Credit: Pak Kin Wong)

New Diagnostic Workflow Identifies Bloodstream Pathogens and Antibiotic Response in Hours

Sepsis is a life-threatening complication of infection that affects more than 1.5 million patients annually in the United States and contributes to roughly one in three in-hospital deaths.... Read more

Pathology

view channel
Image: Researchers evaluated AI models that quantify tumor-infiltrating lymphocytes (TIL) on routine breast tissue slides, where higher TIL levels reflect stronger antitumor response and improved breast cancer outcomes (Image Credit: Shutterstock)

AI Matches Pathologists in Predicting Breast Cancer Prognosis from Immune Cells

Breast cancer is the most common cancer in Australian women, with more than 20,000 cases each year. Prognosis can be informed by counting tumor-infiltrating lymphocytes (TILs) on routine pathology slides,... Read more

Industry

view channel
Image: RaDaR ST uses a tumor-informed approach that identifies up to 48 patient-specific variants through whole-exome sequencing and tracks those variants in plasma to detect circulating tumor DNA (ctDNA) at very low variant allele fractions (VAFs) (Photo courtesy of Neogenomics)

Tumor-Informed MRD Assay Gains Medicare Coverage for Immunotherapy Monitoring

NeoGenomics’ RaDaR ST molecular residual disease (MRD) assay has received expanded coverage from the Centers for Medicare & Medicaid Services’ Molecular Diagnostic Services Program (MolDX) for monitoring... Read more